The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention‐Deficit/Hyperactivity Disorder | Zendy

Storebø Ole Jakob | Zendy; Faltinsen Erlend | Zendy; Zwi Morris | Zendy; Simonsen Erik | Zendy; Gluud Christian | Zendy

Premium

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention‐Deficit/Hyperactivity Disorder

Author(s) -

Storebø Ole Jakob,

Faltinsen Erlend,

Zwi Morris,

Simonsen Erik,

Gluud Christian

Publication year - 2018

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt.1149

Subject(s) - methylphenidate , attention deficit hyperactivity disorder , attention deficit disorder , psychiatry , psychology , attention deficit , medicine , clinical psychology

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention‐deficit/hyperactivity disorder ( ADHD ). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD . This article explores the main findings in relation to evidence‐based practice and our current understanding of ADHD .[1][Storebø, O.J., 2015], [2][Storebø, O.J., 2018]

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research